GPR35 is a functional receptor in rat dorsal root ganglion neurons
- PMID: 17996730
- DOI: 10.1016/j.bbrc.2007.10.197
GPR35 is a functional receptor in rat dorsal root ganglion neurons
Abstract
GPR35, previously an orphan G-protein coupled receptor, is a receptor for kynurenic acid. Here we examine the distribution of GPR35 in the rat dorsal root ganglion (DRG) and the effects of its selective activation. GPR35 was expressed predominantly by small- to medium-diameter neurons of the DRG. Many of these same neurons also expressed the transient receptor potential vanilloid 1 channel, a nociceptive neuronal marker. The GPR35 agonists kynurenic acid and zaprinast inhibited forskolin-stimulated cAMP production by cultured rat DRG neurons. Inhibition required G(i/o) proteins as the effect was completely abolished by pretreatment with pertussis toxin. This is the first study to report the expression and function of GPR35 in rat nociceptive DRG neurons. We propose that GPR35 modulates nociception and that continued study of this receptor will provide additional insight into the role of kynurenic acid in pain perception.
Similar articles
-
Kynurenic acid and zaprinast induce analgesia by modulating HCN channels through GPR35 activation.Neuropharmacology. 2016 Sep;108:136-43. doi: 10.1016/j.neuropharm.2016.04.038. Epub 2016 Apr 27. Neuropharmacology. 2016. PMID: 27131920
-
G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast.Neuropharmacology. 2011 Jun;60(7-8):1227-31. doi: 10.1016/j.neuropharm.2010.11.014. Epub 2010 Nov 24. Neuropharmacology. 2011. PMID: 21110987
-
Upregulation and redistribution of ephrinB and EphB receptor in dorsal root ganglion and spinal dorsal horn neurons after peripheral nerve injury and dorsal rhizotomy.Eur J Pain. 2008 Nov;12(8):1031-9. doi: 10.1016/j.ejpain.2008.01.011. Epub 2008 Mar 5. Eur J Pain. 2008. PMID: 18321739
-
The development and modulation of nociceptive circuitry.Curr Opin Neurobiol. 2006 Aug;16(4):460-6. doi: 10.1016/j.conb.2006.06.002. Epub 2006 Jul 7. Curr Opin Neurobiol. 2006. PMID: 16828278 Review.
-
Orthologue selectivity and ligand bias: translating the pharmacology of GPR35.Trends Pharmacol Sci. 2011 May;32(5):317-25. doi: 10.1016/j.tips.2011.02.002. Epub 2011 Mar 9. Trends Pharmacol Sci. 2011. PMID: 21392828 Review.
Cited by
-
Changing the face of kynurenines and neurotoxicity: therapeutic considerations.Int J Mol Sci. 2015 Apr 29;16(5):9772-93. doi: 10.3390/ijms16059772. Int J Mol Sci. 2015. PMID: 25938971 Free PMC article. Review.
-
Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35.ACS Pharmacol Transl Sci. 2020 Jul 29;3(5):801-812. doi: 10.1021/acsptsci.0c00079. eCollection 2020 Oct 9. ACS Pharmacol Transl Sci. 2020. PMID: 33073184 Free PMC article. Review.
-
Involvement of the kynurenine pathway in human glioma pathophysiology.PLoS One. 2014 Nov 21;9(11):e112945. doi: 10.1371/journal.pone.0112945. eCollection 2014. PLoS One. 2014. PMID: 25415278 Free PMC article.
-
Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity.Front Endocrinol (Lausanne). 2021 Aug 23;12:715877. doi: 10.3389/fendo.2021.715877. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34497585 Free PMC article. Review.
-
Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.Br J Pharmacol. 2011 Feb;162(3):733-48. doi: 10.1111/j.1476-5381.2010.01082.x. Br J Pharmacol. 2011. PMID: 20958291 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources